259 filings
Page 4 of 13
8-K
sfuzgcc6b41t3dixc
24 Feb 22
Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress
6:45am
8-K
allhsmze y2t8ay8
16 Feb 22
Other Events
7:00am
8-K
vzzsjqja
10 Jan 22
Regulation FD Disclosure
7:31am
S-3ASR
jkfpz a1aqloaij
17 Dec 21
Automatic shelf registration
12:00am
8-K
50na2 gl1c
1 Dec 21
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
7:00am
8-K
ceb0 3fblm3gqs
2 Nov 21
Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
7:30am
8-K
6c8ivcp t69
19 Oct 21
Other Events
8:01am
8-K
hczrq890 iyk1ohdi5t
3 Aug 21
Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
7:01am
8-K
mkkbi
15 Jun 21
Other Events
6:50am
8-K
j72c fu8g6r
10 Jun 21
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
kgmh9edhm0ycub
4 May 21
Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
7:14am
DEFA14A
lpldp3mjo3
29 Apr 21
Additional proxy soliciting materials
4:09pm
8-K
yeejgds9 7wy
12 Apr 21
Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
7:17am
8-K
p56st
18 Mar 21
Sage Therapeutics Announces Continued Positive Zuranolone Data for Both
6:55am
8-K
htfoxj9 3sg
17 Mar 21
Departure of Directors or Certain Officers
8:04am
S-8
0qef1164n9rzj ce
24 Feb 21
Registration of securities for employees
7:46am